Criteria for alpha 1-antitrypsin substitution.
The pharmacology and safety of substitution treatment intravenously with alpha 1-antitrypsin (AAT) in patients deficient of AAT has been thoroughly investigated. The clinical efficacy of the treatment has so far not been established. The difficulties and uncertainties involved in defining the right persons for treatment, and determining the right time for a possible start of treatment are discussed. A controlled trail with participation of several European countries is suggested.
Viskum
K
K
Department of Pulmonary Medicine P, Bispebjerg Hospital, Copenhagen, Denmark.
Kok-Jensen
A
A
D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011656:Pulmonary Emphysema / Q000235:genetics / Q000628:therapy*; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage* / Q000235:genetics; D019896:alpha 1-Antitrypsin Deficiency
D000515:alpha 1-Antitrypsin